

Literatur für onkologie heute 05/2021

SCHWERPUNKT: MAMMA- UND OVARIALKARZINOM

Praxisrelevanz der Genetik in der Gynäkologischen Onkologie (S. 9–20)

B. Ataseven, N. Pauly, A. du Bois

1.

https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/krebs_in_deutschland_2019.pdf;jsessionid=2570AF7C1C6BFEEEE3203FF14DD227F3.1_cid290?_blob=publicationFile.2019

2. Davidson BA et al. Preferences of women with epithelial ovarian cancer for aspects of genetic testing. *Gynecol Oncol Res Pract* 2019; 6: 1

3. <https://www.onkozeit.de/informationen-zertifizierung/hinweise-downloads/genetische-beratung-familiaeres-ovarialkarzinom-lynch-syndrom-algorithmus-bei-verdacht-auf-lynch-syndrom/>

4. Ataseven B et al. Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer - Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation? *Geburtshilfe Frauenheilkd* 2020; 80: 932–40

5. Harter P et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). *PLoS One* 2017; 12: e0186043

6. Kahn RM et al. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? *Cancer* 2019; 125: 3172–83

7. <https://www.konsortium-familiaerer-brustkrebs.de/informationen/informative-links/>. 2021

8. McClain MR et al. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. *Genet Med* 2005; 7: 28–33

9. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. *Am J Hum Genet* 1995; 57: 1457–62

10. Risch HA et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *J Natl Cancer Inst* 2006; 98: 1694–706

11. Daly MB et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. *J Natl Compr Canc Netw* 2017; 15: 9–20

12. Hampel H et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. *Genet Med* 2015; 17: 70–87

13. Moyer VA, Force USPST. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014; 160: 271–81

14. Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013; 105: 812–22

15. Kuchenbaecker KB et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA* 2017; 317: 2402–416

16. Graeser MK et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2009; 27: 5887–92

17. Rhiem K et al. The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. *Breast Cancer Res* 2012; 14: R156

18. Hartmann LC et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. *J Natl Cancer Inst* 2001; 93: 1633–37
19. Meijers-Heijboer H et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001; 345: 159–64
20. Rebbeck TR et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 2004; 22: 1055–62
21. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. *N Engl J Med* 2002; 346: 1660–62
22. Kauff ND et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002; 346: 1609–15
23. <https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/>. 2021
24. Mehrad M et al. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. *Adv Anat Pathol* 2010; 17: 293–302
25. Medeiros F et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. *Am J Surg Pathol* 2006; 30: 230–236
26. Lamb JD et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. *Am J Obstet Gynecol* 2006; 194: 1702–9
27. Reitsma W et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. *Eur J Cancer* 2013; 49: 132–41
28. Zakhour M et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. *Gynecol Oncol* 2016; 143: 231–35
29. Powell CB et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. *J Clin Oncol* 2005; 23: 127–32
30. Rush SK et al. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. *Gynecol Oncol* 2020; 157: 514–20
31. Ricciardi E et al. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. *Anticancer Res* 2017; 37: 5241–248
32. Colombo N et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *Ann Oncol* 2019; 30: 672–705
33. Casey MJ et al. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. *Gynecol Oncol* 2005; 97: 457–67
34. Tai YC et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst* 2007; 99: 1811–14
35. Silvestri V et al. Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncol* 2020; 6: 1218–30
36. Eierstockkrebs DKFB-u. <https://www.konsortium-familiaerer-brustkrebs.de/konsensusempfehlung/>. 2021
37. Moran A et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. *Fam Cancer* 2012; 11: 235–42
38. <https://www.konsortium-familiaerer-brustkrebs.de/konsensusempfehlung/>

39. Lu KH et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. *Obstet Gynecol* 2005; 105: 569–74
40. ASK2ME. <https://ask2me.org/>
41. 2019 S-LKK.
https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Kolorektales_Karzinom/Version_2/LL_KRK_Langversion_2.1.pdf
42. Endometriumkarzinom S-L 2018.
<https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/>
43. Mamma AK 2021.
<https://www.ago-online.de/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-mamma>
444. Fasching PA et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. *J Clin Oncol* 2018; 36: 2281–87
45. Hahnen E et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. *JAMA Oncol* 2017; 3: 1378–85
46. Tutt A et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. *Nat Med* 2018; 24: 628–37
47. Robson M et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *N Engl J Med* 2017; 377: 523–33
48. Litton JK et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. *N Engl J Med* 2018; 379: 753–63
49. Alsop K et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. *J Clin Oncol* 2012; 30: 2654–63
50. Mirza MR et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med* 2016; 375: 2154–64
51. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. *J Clin Oncol* 2008; 26: 3259–67
52. Bolton KL et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. *JAMA* 2012; 307: 382–90
53. Candido-dos-Reis FJ et al. Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clin Cancer Res* 2015; 21: 652–57
54. Labidi-Galy SI et al. Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer. *Clin Cancer Res* 2018; 24: 326–33
55. Coleman RL et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. *N Engl J Med* 2019; 381: 2403–15
56. Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018; 379: 2495–505
57. Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019; 381: 2416–28
58. Gonzalez-Martin A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019; 381: 2391–402
59. Cancer Genome Atlas Research N, Kandoth C, Schultz N et al. Integrated genomic characterization of endometrial carcinoma. *Nature* 2013; 497: 67–73

60. Johnatty SE et al. Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. *Gynecol Oncol* 2017; 147: 381–87
61. Long B et al. Cancer susceptibility gene mutations in type I and II endometrial cancer. *Gynecol Oncol* 2019; 152: 20–25
62. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999; 116: 1453–56
63. Umar A et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004; 96: 261–68
64. PEREMM5. <https://premm.dfci.harvard.edu/>
65. Pauly N et al. Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience. *Arch Gynecol Obstet* 2021 Mar 12. doi: 10.1007/s00404-021-06006-w
66. Boks DE et al. Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. *Int J Cancer* 2002; 102: 198–200

Die Therapie des epithelialen Ovarialkarzinoms (S. 21–31)

N. Pauly, A. du Bois, B. Ataseven

1. Robert Koch-Institut e.V. GdeKiD. Krebs in Deutschland 2015/2016. 2019, <http://dx.doi.org/10.25646/5977>
2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, 2020, AWMF-Registernummer: 032/035OL, <https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/>, Letzter Zugriff: 25.01.2021
3. Colombo N et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *Int J Gynecol Cancer* 2019; ijgc-2019-000308
4. Trimbos B et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. *J Natl Cancer Inst* 2010; 102: 982–87
5. du Bois A et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. *Cancer* 2009; 115: 1234–44
6. Heitz F et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. *Ann Surg Oncol* 2018; 25: 2053–59
7. Trimbos JB et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. *J Natl Cancer Inst* 2003; 95: 105–12
8. Kahl A et al. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer. *Ann Surg Oncol* 2017; 24: 3692–99
9. Ataseven B et al. Skeletal Muscle Attenuation (Sarcopenia) Predicts Reduced Overall Survival in Patients with Advanced Epithelial Ovarian Cancer Undergoing Primary Debulking Surgery. *Ann Surg Oncol* 2018; 25: 3372–79
10. Harter P et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. *N Engl J Med* 2019; 380: 822–32

11. Vergote I et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. *N Engl J Med* 2010; 363: 943–53
12. du Bois A, Baert T, Vergote I. Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. *J Clin Oncol* 2019; 37: 2398–405
13. Kehoe S et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. *The Lancet* 2015; 386: 249–57
14. ClinicalTrials.gov. Trial on Radical Upfront Surgery in Advanced Ovarian Cancer (TRUST). In. <https://clinicaltrials.gov/ct2/show/NCT02828618>; 2016
15. du Bois A et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. *J Natl Cancer Inst* 2003; 95: 1320–29
16. Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011; 365: 2473–83
17. Perren TJ et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011; 365: 2484–96
18. Network CGAR. Integrated genomic analyses of ovarian carcinoma. *Nature* 2011; 474: 609–15
19. Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2018; 379: 2495–505
20. Banerjee S et al. 811MO: Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. *Ann Oncol* 2020; 31: S613
21. Gonzalez-Martin A et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med* 2019; 381: 2391–402
22. Ray-Coquard I et al. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. *N Engl J Med* 2019; 381: 2416–28
23. Coleman RL et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. *New England Journal of Medicine* 2019; 381: 2403–15
24. Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. *Hum Pathol* 2018; 80: 11–27
25. Grabowski JP et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. *Gynecol Oncol* 2016; 140: 457–62
26. Pauly N et al. Low-grade Serous Tumors: Are We Making Progress? *Curr Oncol Rep* 2020; 22: 8
27. Gershenson DM et al. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. *Gynecol Oncol* 2012; 125: 661–66
28. Ledermann JA et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial. *Gynecol Oncol* 2020; 159: 13–14
29. Roche. Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer. In; 2020
30. Harter P et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. *Ann Surg Oncol* 2009; 16: 1324–30
31. Harter P et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. *Int J Gynecol Cancer* 2011; 21: 289–95
32. Du Bois A et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. *Journal of Clinical Oncology* 2020; 38: 6000

33. Shi T et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2021; 22: 439–49
34. Coleman RL et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. *N Engl J Med* 2019; 381: 1929–39
35. Baert T et al. The systemic treatment of recurrent ovarian cancer revisited. *Ann Oncol* 2021; S0923-7534(21)00155-1
36. Parmar MK et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet (London, England)* 2003; 361: 2099–106
37. Pfisterer J et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. *J Clin Oncol* 2006; 24: 4699–707
38. Pujade-Lauraine E et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. *J Clin Oncol* 2010; 28: 3323–29
39. Pignata S et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GClG Study. *J Clin Oncol* 2017; 35: 3347–53
40. Colombo N et al. LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line. *Ann Oncol* 2020; 31: S1161
41. Poveda A et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. *Ann Oncol* 2011; 22: 39–48
42. Gomez R et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. *Int J Gynecol Cancer* 2009; 19: 1284–87
43. Aghajanian C et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. *J Clin Oncol* 2012; 30: 2039–45
44. Pfisterer J et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. *Lancet Oncol* 2020; 21: 699–709
45. Pujade-Lauraine E et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. *J Clin Oncol* 2014; 32: 1302–8
46. Pignata S et al. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. *The Lancet Oncology* 2021; 22: 267–76
47. Ledermann JA et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. *Lancet Oncol* 2016; 17: 1579–89
48. Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a *BRCA1/2* mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol* 2017; 18: 1274–84
49. Poveda A et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. *J Clin Oncol* 2020; 38(15)suppl, abstr. #6002
50. Mirza MR et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med* 2016; 375: 2154–64

51. Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet* 2017; 390: 1949–61
52. Penson RT et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. *J Clin Oncol* 2020; 38: 1164–74
53. Kristeleit R LA et al. Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase 3 study. Presented at: Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer; March 19–25, 2021
54. Gershenson DM et al. LBA61 – A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer. *Ann Oncol* 2019; 30: v897–v898
55. Pujade-Lauraine E et al. OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer. *Ann Oncol* 2017; 28: v351–v352
56. Kurtz JE et al. ATALANTE (ENGOT-ov29): A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab. *J Clin Oncol* 2018; 36(15)suppl, Abstr. #TPS5607
57. Marme F et al. AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC). *J Clin Oncol* 2019; 37(15)suppl, abstr. # TPS5601
58. González-Martín A et al. ENGOT-Ov41/GEICO-69-O/ANITA trial: A phase III randomized, double-blinded trial of platinum-based chemotherapy (CT) with or without atezolizumab (ATZ) followed by niraparib maintenance with or without ATZ in patients with recurrent ovarian, tubal or peritoneal cancer (OC) and platinum treatment-free interval (TFIp) > 6 months. *J Clin Oncol* 2019; 37(15)suppl, abstr. # TPS5599
59. Ledermann J et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. *N Engl J Med* 2012; 366: 1382–92

Mammakarzinom und Schwangerschaft – Empfehlungen für Klinik und Praxis (S. 39–44)

S. Seiler, S. Loibl

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; 68(1): 7-30
2. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). *Krebs in Deutschland 2011/2012*. 10. Ausgabe. Berlin, 2015
3. Martin JA et al. Births: Final Data for 2019. *National Vital Statistics Reports*; vol 70 no 2. Hyattsville, MD: National Center for Health Statistics. 2021
4. Haas JF. Pregnancy in association with a newly diagnosed cancer: a population-based epidemiologic assessment. *Int J Cancer* 1984; 34(2): 229–35
5. Abenhaim HA et al. Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy. *Breast J* 2012; 18(6): 564–8
6. Lee YY et al. Incidence and outcomes of pregnancy-associated cancer in Australia, 1994–2008: a population-based linkage study. *BJOG* 2012; 119(13): 1572–82
7. Middleton LP et al. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. *Cancer* 2003; 98(5): 1055–60

8. Loibl S et al. Treatment of breast cancer during pregnancy: an observational study. *Lancet Oncol* 2012; 13(9): 887–96
9. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. *Arch Surg* 2003; 138(1) :91–8
10. Nettleton et al. A Breast cancer during pregnancy: quantifying the risk of treatment delay. *Obstet Gynecol* 1996; 87:414–418
11. Loibl S et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. *JAMA Oncol* 2015; 1(8): 1145–53
12. Robbins J, Jeffries D, Roubidoux M, Helvie M. Accuracy of diagnostic mammography and breast ultrasound during pregnancy and lactation. *AJR Am J Roentgenol* 2011; 196(3): 716–22
13. Amant F et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. *Eur J Cancer* 2010; 46(18): 3158–68
14. Vashi R et al. Breast imaging of the pregnant and lactating patient: imaging modalities and pregnancy-associated breast cancer. *AJR Am J Roentgenol* 2013; 200(2): 321–28
15. Nguyen CP, Goodman LH. Fetal risk in diagnostic radiology. *Semin Ultrasound CT MR* 2012; 33(1): 4–10
16. Ray JG et al. Association between MRI exposure during pregnancy and fetal and childhood outcomes. *JAMA* 2016; 316(9): 952–61
17. Wang PI et al. Imaging of pregnant and lactating patients: part 1, evidence-based review and recommendations. *AJR Am J Roentgenol* 2012; 198(4): 778–84
18. Roberts CC et al. ACR appropriateness criteria on metastatic bone disease. *J Am Coll Radiol* 2010; 7(6): 400–9
19. Amant F et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: Results from an international collaborative study. *J Clin Oncol* 2013; 31(20): 2532–9
20. Amant F et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. *Eur J Cancer* 2010; 46(18): 3158–68
21. Azim HA Jr et al. The biological features and prognosis of breast cancer diagnosed during pregnancy: a case-control study. *Acta Oncol* 2012; 51(5): 653–61
22. Toesca A et al. Locoregional treatment of breast cancer during pregnancy. *Gynecol Surg* 2014; 11(4): 279–84
23. Lohsiriwat V et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. *Breast* 2013; 22(5): 657–60
24. Han SN et al. Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. *Breast Cancer Res Treat* 2018 ; 168(2): 551–57
25. Huang J et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. *J Clin Oncol* 2003; 21(3): 555–63
26. Berry DL et al. Management of breast cancer during pregnancy using a standardized protocol. *J Clin Oncol* 1999; 17(3): 855–61
27. Calsteren KV et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. *Int J Gynecol Cancer* 2010; 20(9): 1456–64
28. de Haan J et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. *Lancet Oncol* 2018; 19(3): 337–46

29. Rodriguez-Pinilla E, Martinez-Frias ML. Corticosteroids during pregnancy and oral clefts: a case-control study. *Teratology* 1998; 58: 2–5
 30. van Hasselt JG et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. *Ann Oncol* 2014; 25(10): 2059–65
 31. Nulman I, et al. Neurodevelopment of children exposed in utero to treatment of maternal malignancy. *Br J Cancer* 2001; 85(11): 1611–8
 32. Amant F et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *International Network on Cancer, Infertility, and Pregnancy (INCIP)*. *N Engl J Med* 2015; 373(19): 1824–34
 33. Fachinformation Herceptin®, Stand März 2021
 34. Loibl S et al. Breast carcinoma during pregnancy. *International recommendations from an expert meeting*. *Cancer* 2006; 106(2): 237–46
-

Komplementärmedizin in der Gynäkologischen Onkologie – Resilienz und Insomnie (S. 50–58)

P. Klose, A. Paul, G. Dobos, S. Kümmel, P. Voiß

1. Komplementärmedizin.
[https://de.wikipedia.org/wiki/Alternativmedizin#:~:text=Alternativmedizin%20\(auch%20Alternative%20Medizin\)%20und,begr%C3%BCndeten%20Methoden%20der%20Medizin%20verstehen](https://de.wikipedia.org/wiki/Alternativmedizin#:~:text=Alternativmedizin%20(auch%20Alternative%20Medizin)%20und,begr%C3%BCndeten%20Methoden%20der%20Medizin%20verstehen). Wikipedia.
Letzter Aufruf: 18.03.2021
2. NIH complementary and integrative health agency gets new name. <https://www.nih.gov/news-events/news-releases/nih-complementary-integrative-health-agency-gets-new-name>. National Institutes of Health. Letzter Aufruf: 18.03.2021
3. NCCIH Funding: Appropriations History. <https://www.nccih.nih.gov/about/budget/nccih-funding-appropriations-history> und <https://www.nccih.nih.gov/about/budget/complementary-and-alternative-medicine-funding-by-nih-institutecenter>. National Institutes of Health. Letzter Aufruf: 18.03.2021
4. SIO. <https://integrativeonc.org/>. Letzter Aufruf: 18.03.2021
5. PRIO. <https://prio-dkg.de/>. Letzter Aufruf: 18.03.2021
6. AGO_Kommission IMed. <https://www.ago-online.de/ago-kommissionen/kommission-imed>. Letzter Aufruf: 18.03.2021
7. Witt CM et al. Kompetenznetz Komplementärmedizin in der Onkologie (KOKON). Ein wissenschaftlicher Beitrag zur Verbesserung der Versorgung. *FORUM* 2017; 32: 416–23
8. Haidinger R, Bauerfeind I. Long-Term Side Effects of Adjuvant Therapy in Primary Breast Cancer Patients: Results of a Web-Based Survey. *Breast Care (Basel)* 2019; 14: 111–6
9. Doege D et al. Health-related quality of life in long-term disease-free breast cancer survivors versus female population controls in Germany. *Breast Cancer Res Treat* 2019; 175: 499–510
10. Doege D et al. Age-specific prevalence and determinants of depression in long-term breast cancer survivors compared to female population controls. *Cancer Med* 2020; 9: 8713–21
11. Ranieri J, Guerra F, Di Giacomo D. Role of Metacognition Thinking and Psychological Traits in Breast Cancer Survivorship. *Behav Sci (Basel)* 2020; 10(9): 135
12. Farber F, Rosendahl J. The Association Between Resilience and Mental Health in the Somatically Ill. *Dtsch Arztebl Int* 2018; 115: 621–7

13. Kalisch R, Muller MB, Tuscher O. A conceptual framework for the neurobiological study of resilience. *Behav Brain Sci* 2015; 38: e92
14. Mohlin A et al. Psychological Resilience and Health-Related Quality of Life in Swedish Women with Newly Diagnosed Breast Cancer. *Cancer Manag Res* 2020; 12: 12041–51
15. Ludolph P. Resilienzfördernde Interventionen bei Patienten mit Krebs. *Dtsch Arztebl Int* 2019; 116(51-52): 865–72
16. Linz SH et al. Interventionen zur Resilienzförderung bei Erwachsenen. *Psychother Psych Med* 2020; 70: 11–21
17. Lewson AB et al. Symptom experiences in post-treatment cancer survivors: associations with acceptance and commitment therapy constructs. *Support Care Cancer* 2020; doi: 10.1007/s00520-020-05854-7
18. Schell LK et al. Mindfulness-based stress reduction for women diagnosed with breast cancer. *Cochrane Database Syst Rev* 2019; 3: CD011518
19. Haller H et al. Mindfulness-based interventions for women with breast cancer: an updated systematic review and meta-analysis. *Acta Oncol* 2017; 56: 1665–76
20. Dobos G et al. Integrating mindfulness in supportive cancer care: a cohort study on a mindfulness-based day care clinic for cancer survivors. *Support Care Cancer* 2015; 23: 2945–55
21. Jeitler M et al. Mind-body medicine and lifestyle modification in supportive cancer care: A cohort study on a day care clinic program for cancer patients. *Psychooncology* 2017; 26: 2127–34
22. Haller H et al. Effects of an Integrative Mind-body-medicine Group Program for Breast Cancer Patients during Chemotherapy: An Observational Study. *Curr Pharm Des* 2021; 27(8): 1112–20
23. Witt CM et al. Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial. *Breast Cancer Research and Treatment* 2015; 149: 449–60
24. Oei SL et al. Evaluation of the effects of integrative non-pharmacological interventions on the internal coherence and resilience of breast cancer patients. *Support Care Cancer* 2021; 29(3): 1413–21
25. Lutgendorf SK et al. Social influences on clinical outcomes of patients with ovarian cancer. *J Clin Oncol* 2012; 30: 2885–90
26. Lai HL et al. Resilience and coping styles as predictors of health outcomes in breast cancer patients: A structural equation modelling analysis. *Eur J Cancer Care (Engl)* 2020; 29: e13161
27. Savard J et al. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. *J Clin Oncol* 2011; 29: 3580-6
28. Leysen L et al. Prevalence and risk factors of sleep disturbances in breast cancersurvivors: systematic review and meta-analyses. *Support Care Cancer* 2019; 27: 4401–33
29. Strollo SE et al. Cancer-related problems, sleep quality, and sleep disturbance among long-term cancer survivors at 9-years post diagnosis. *Sleep Med* 2020; 65: 177–85
30. Irwin MR. Why sleep is important for health: a psychoneuroimmunology perspective. *Annu Rev Psychol* 2015; 66: 143–72
31. Irwin MR, Olmstead R, Carroll JE. Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. *Biol Psychiatry* 2016; 80: 40–52
32. Palesh O et al. Actigraphy-measured sleep disruption as a predictor of survival among women with advanced breast cancer. *Sleep* 2014; 37: 837–42
33. Bach L, Kalder M, Kostev K. Depression and sleep disorders are associated with early mortality in women with breast cancer in the United Kingdom. *J Psychiatr Res* 2020; S0022-3956(20)31096-7
34. Jacob L et al. Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case-control study of 11,412 women. *Breast Cancer Res Treat* 2018; 171: 443–8

35. Liou KT et al. The Relationship Between Insomnia and Cognitive Impairment in Breast Cancer Survivors. *JNCI Cancer Spectr* 2019; 3: pkz041
36. Garland SN et al. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. *J Clin Oncol* 2014; 32: 449–57
37. Cramer H et al. Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. *Cochrane Database Syst Rev* 2017; 1: CD010802
38. Lin PJ et al. Influence of Yoga on Cancer-Related Fatigue and on Mediation Relationships Between Changes in Sleep and Cancer-Related Fatigue: A Nationwide, Multicenter Randomized Controlled Trial of Yoga in Cancer Survivors. *Integr Cancer Ther* 2019; 18: 1534735419855134
39. Mustian KM et al. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. *J Clin Oncol* 2013; 31: 3233–41
40. Kreutz C, Schmidt ME, Steindorf K. Effects of physical and mind-body exercise on sleep problems during and after breast cancer treatment: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2019; 176: 1–15
41. Chiu HY et al. Walking improves sleep in individuals with cancer: a meta-analysis of randomized, controlled trials. *Oncol Nurs Forum* 2015; 42: e54–62
42. Garland SN et al. Acupuncture Versus Cognitive Behavioral Therapy for Insomnia in Cancer Survivors: A Randomized Clinical Trial. *J Natl Cancer Inst* 2019; 111(12): 1323–31
43. Garland SN et al. Comparative effectiveness of electro-acupuncture versus gabapentin for sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. *Menopause* 2017; 24: 517–23
44. Zick SM et al. Investigation of 2 Types of Self-administered Acupressure for Persistent Cancer-Related Fatigue in Breast Cancer Survivors: A Randomized Clinical Trial. *JAMA Oncol* 2016; 2: 1470–6
45. Troger W et al. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone. *Breast Cancer (Auckl)* 2009; 3: 35–45
46. Troger W et al. Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial. *Evid Based Complement Alternat Med* 2014; 2014: 430518
47. Yang HL et al. The effects of warm-water footbath on relieving fatigue and insomnia of the gynecologic cancer patients on chemotherapy. *Cancer Nurs* 2010; 33: 454–60
48. Wylegalla C. https://www.kok-krebsgesellschaft.de/wp-content/uploads/2015/07/lavendeloel_dkk_2008.pdf. Lavendelölaufgaben bei onkologischen Patienten mit Schlafstörungen – Eine randomisierte, kontrollierte Untersuchung von Lavendelölaufgaben im Vergleich mit Mandelölaufgaben. *Zeitschrift für Palliativmedizin* 2010; 11: V1_3
49. Hwang E, Shin S. The effects of aromatherapy on sleep improvement: a systematic literature review and meta-analysis. *J Altern Complement Med* 2015; 21: 61–8
50. Dyer J et al. The use of aromasticks to help with sleep problems: A patient experience survey. *Complement Ther Clin Pract* 2016; 22: 51–8